Title: Guillain- Barré Syndrome<br/>Author: Danya Khoujah<br/><a href='http://umem.org/profiles/faculty/739/'>[Click to email author]</a><hr/><p>
        <span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">It's respiratory infection and flu vaccine season! Time to brush up on Guillain-Barré Syndrome..</span></span></p>
<p>
        <span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">- It is the most common cause of acute or subacute flaccid weakness worldwide</span></span></p>
<p>
        <span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">- 70% of cases are preceded by an infection in the past 10-14 days, but most are minimized or forgotten by the patient. 40% of these infections are by <em>Campylobacter jejuni.</em></span></span></p>
<p>
        <span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">- 30% develop respiratory failure requiring intubation and ventilation</span></span></p>
<p>
        <span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">- Half of the patients will develop their maximum weakness by 2 weeks, most will develop it by 4 weeks.</span></span></p>
<fieldset><legend>References</legend>

                <p>
        <style type="text/css">
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 7.0px Helvetica}   </style>
</p>
<p class="p1">
        Donofrio PD. Guillain-Barré Syndrome. Continuum 2017;23(5):1295–1309.</p>
</fieldset>